Eptifibatide (Integrilin)
Overview
A synthetic cyclic heptapeptide modeled after the KGD (Lys-Gly-Asp) disintegrin sequence found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Eptifibatide is a potent, reversible glycoprotein IIb/IIIa receptor antagonist that blocks the final common pathway of platelet aggregation by preventing fibrinogen and von Willebrand factor binding to activated platelets.
Key Research Findings
FDA-approved for acute coronary syndrome and percutaneous coronary intervention. PURSUIT trial showed 1.5% absolute reduction in death or MI at 30 days in ACS patients (NEJM, 1998). ESPRIT trial demonstrated 37% relative reduction in death, MI, or urgent target vessel revascularization at 48 hours in PCI patients. Short half-life (2.5 hours) allows rapid recovery of platelet function after discontinuation.
Intravenous
FDA Approved
Interested in Eptifibatide (Integrilin)?
Find a verified provider experienced with Eptifibatide (Integrilin) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Eptifibatide (Integrilin) ProviderRelated Peptides
Nesiritide (Natrecor)
FDA ApprovedA recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide naturally produced by ventricular cardiomyocytes in response to volume overload and wall stress. Nesiritide binds natriuretic peptide receptor A (NPR-A), activating guanylyl cyclase and increasing intracellular cGMP to produce venous, arterial, and coronary vasodilation, natriuresis, and suppression of the renin-angiotensin-aldosterone and sympathetic nervous systems.
Angiotensin II (Giapreza)
FDA ApprovedA synthetic form of the endogenous octapeptide angiotensin II, the primary effector of the renin-angiotensin system. Angiotensin II acts on AT1 receptors on vascular smooth muscle to produce potent vasoconstriction, and on the adrenal cortex to stimulate aldosterone release. Exogenous administration raises blood pressure in vasodilatory shock refractory to conventional vasopressors by restoring vascular tone through a mechanism complementary to catecholamine vasopressors.
Serelaxin (Relaxin-2)
InvestigationalSerelaxin is a recombinant form of human relaxin-2, a naturally occurring peptide hormone composed of two chains linked by disulfide bonds. It acts via the relaxin family peptide receptor 1 (RXFP1) to promote vasodilation, inhibit fibrosis, and modulate hemodynamics. The therapeutic rationale targets acute heart failure by improving renal perfusion and reducing vascular resistance.
Carperitide (h-ANP)
FDA ApprovedCarperitide is a recombinant form of human atrial natriuretic peptide consisting of 28 amino acids. It activates guanylyl cyclase A receptors, increasing intracellular cyclic GMP to promote vasodilation, natriuresis, and diuresis. The peptide reduces cardiac preload and afterload while inhibiting the renin-angiotensin-aldosterone system, providing therapeutic benefit in acute heart failure.